All PlansCoverageLow impact
Genetic Testing for Lipoprotein(a) Variant(s) as a Decision Aid for Aspirin Treatment
Blue Cross & Blue Shield of Mississippi·Cardiology, Family Medicine, Internal Medicine·Medical Policy
We identified it
Jun 20, 2026
Summary
This policy establishes that genetic testing for the LPA rs3798220 allele (LPA-Aspirin Genotype) to guide aspirin treatment decisions is considered investigational and not covered. The policy clarifies that this testing should not be billed as a covered service.
Action Required
Immediately: Billing team should verify that genetic testing for LPA rs3798220 allele (LPA-Aspirin Genotype) is not being billed as a covered service. If any claims are being submitted for this testing, inform providers that it is considered investigational and will be denied. Update billing system notes to flag this as non-covered investigational testing.